The possibilities to define thresholds in general pharmacology and toxicology depend upon the proper knowledge and determination of the most sensitive parameters and relevant targets leading to clinical effects or toxicity. We are generally confronted with the statistical summation of very numerous individual responses and effects at the enzymological, sub-cellular, cellular, organ, or systemic level. In consequence, biological actions of chemicals reveal typical dose-response characteristics described by simple mathematics, and more or less sharp thresholds. Thresholds and targets can change after single and repeated (cumulative) doses by means of altered kinetics and metabolism, by adaptation and modified sensitivity of targets and/or receptors. Most sensitive targets and parameters do not always determine the real thresholds for clinical toxicity. Threshold and specificity of carcinogens can also be modified by similar conditions mentioned. Nutritional factors play an important role in experimental car-dnogenesis, and also for the cancer incidence in man. Frequently, secondary mechanisms such as overloading, induction of cellular growth, mechanical and chemical irritation and damage, and other conditions have simulated real carcinogenic properties of chemical molecules. The important question on the existence and validity of thresholds in carc/nogenes/s must be connected with a solid evaluation of the mode of action of the individual compounds. Otherwise, mathematical calculations of safety limits, definitions of acceptable risks and no-effect levels lack any biological foundation. Finally, the individual perception and social acceptance of risks reveal certain thresholds.
Andersen, M.E. (1981). Saturable metabolism and its relationship to toxicity. CRC, Critical Rev. Toxicol.9, 105–150.
3.
Atchison, W.D., Yang, K.H., Peterson, R.E. (1981). Dithiobiuret toxicity in the rat Evidence for latency and cumulative dose thresholds. Toxicol. Appl. Pharmacol.67, 166–171.
4.
Barnes, J.M., Denz, F.A. (1954). Experimental methods used in determining chronic toxicity. Pharmacol. Rev.6, 191–242.
5.
Bos, R.P., Brouns, R.M.E., van Doom, R., Theuws, J.L.G., Henderson, P. Th. (1980). The appearance of mutagens in urine of rats after the administration of benzidine and some other aromatic amines. Toxicology76, 113–122.
6.
Boyd, E.M., Dolman, M., Knight, L.M., Sheppard, E.P. (1965). The chronic oral toxicity of caffeine. Canad. J. Physiol. Pharmacol.43, 995–1007.
7.
Boyd, E.M., Hottenroth, S.M.H. (1968). The toxicity of phenacetin at the range of the oral LD50(100 days) in albino rats. Toxicol. Appl. Pharmacol.72, 80–93.
8.
Brinkschulte-Freitas, M., Uehleke, H. (1979). The effect of 2, 2-diethylallyacetamide on hepatic cytochromes in rats and in vitro. Arch. Toxicol.42, 137–146.
9.
Bruce, R.D. (1980): Low dose extrapolation and risk assessment. Chemical Times & Trends, 7980, 19–23.
10.
Carrol, K.K. (1980). Lipids and carcinogenesis. J. Env. Pathol. Toxicol.3, 253–271.
11.
Chu, K.C., Cueto, C, Ward, J.M. (1981). Factors in the evaluation of 200 National Cancer Institute carcinogen bioassays. J. Toxicol. Envrm. Hlth.8, 251–280.
12.
Cohen, E.N., Brown, B.W., Wu, M. (1979). Anesthetic health hazards in the dental operatory. Anesthesiology51, 254.
Crampton, R.F., Cray, T.J.B., Crasso, P., Parke, D.V. (1977a). Long-term studies on chemically induced liver enlargement in rat I. Sustained induction of microsomal enzymes with absence of liver damage on feeding phenobarbitone or butylated hydroxytoluene. Toxicology7, 289–306.
15.
Crampton, R.F., Cray, T.J.B., Crasso, P., Parke, D.V. (1977b). Long-term studies on chemically induced liver enlargement in the rat. II. Transient induction of microsomal enzymes leading to liver damage and nodular hyperplasia produced by safrole and Ponceau MX. Toxicology7, 307–326.
16.
Demopoulos, H.B., Mehlman, M.A. (Eds.) (1980): Cancer and the Environment Pathotox. Publ. Inc., Park Forest South, IL.
17.
DHEW (Formerly Public Health Services Publication No. 149) (1947-1981): Survey of Compounds which have been tested for Carcinogenic Activity, vol. 1-7 and Suppl., U.S. DHEW, National Institutes of Health, Bethesda.
18.
Doll, R., Peto, R. (1981): The causes of cancer Quantitative estimates of avoidable risks of cancer in the United States today. J. Nat Cancer Inst66, 1191–1308.
19.
Druckrey, H., Schildbach, A., Schmahl, D., Preussmann, R. (1963a). Dosis-Wirkungsbeziehungen bei der Krebserzeugung durch 4-Dimethylaminostilben bei Ratten. Z. Krebsforsch.65, 272–288.
20.
Druckrey, H., Schildbach, A., Schmahl, D., Preussmann, R., Ivankovic, S. (1963b). Quantitative Analyse der carcinogenen Wirkung von Dimethylnitrosamin. Arzneimittelforsch.13, 841–851.
21.
Druckrey, H., Preussmann, R., Ivankovic, S., Schmähl, D. (1967). Organotrope carcinogene Wirkungen bei 65 verschiedenen N-Nitroso-Verbindungen an BD-Ratten. Z. Krebsforsch.69, 103–201.
22.
Eckenhausen, F.W., Bennett, D., Beynon, K.I., Elgar, K.E. (1981). Organochlorine pesticide concentrations in perinatal samples from mothers and babies. Arch. Env. Hlth.36, 81–92.
23.
Editorial (1978): Nitrous oxide and the bone-marrow. Lancetii, 613.
24.
Emura, M., Richter-Reichhelm, H.B., Schneider, P., Mohr, U. (1980). Sensitivity of Syrian golden hamster fetal lung cells to benzo(a)pyrene and other polycyclic hydrocarbons in vitro. Toxicology17, 149–155.
25.
Food Safety Council (1978): Quantitative risk assessment In: Proposed System for Food Safety Assessment Fd. Cosm. Toxicol.76 (Suppl. 2) 109–136.
26.
Frank, A.L. (1979). Public health significance of smoking-asbestos interactions. Ann. NY Acad. Sci.330, 971–974.
27.
Fraser, F.C. (1976). The multifactorial threshold concept-Uses and misuses. Teratology14, 267–280.
28.
Fresenius, W., Schneider, W., Roder, R. (1979). Quantitative Untersuchungen über die Fluorid-Ausscheidung in Urin nach dem Genuß von Wasser mit verschiedenen Fluorid-Cehalten. Z. Lebensm. Unters. Forsch.169, 105–110.
29.
Gaddum, J.H. (1956). The estimation of the safe dose. Brit. J. Pharmacol.11, 156–160.
30.
Cehring, P.J., Watanabe, P.G., Young, J.D., Lebeau, J.E. (1976): Metabolic thresholds in assessing carcinogenic hazards. In: Chemicals, Human Health and the Environment, vol. 2, 56–70, DowChemical Co., Midland, Ml.
31.
Gillette, J.R. (1974): Biochemical mechanisms of drug toxicity. Ann. Rev. Pharmacol.14, 271–288.
32.
Graf, W., Beimler, H. J. (1979): Rate of dental caries in youths from communities of both naturally high and low, resp., fluoride content in drinking water. Zbl. Bakt Hyg. I. Abt Orig.B169, 409–428.
33.
Grasso, P., Gray, T.J.B. (1977): Long-term studies on chemically induced liver enlargement in the rat III Structure and behaviour of the hepatic nodular lesions induced by Ponceau MXToxicology7, 327–347.
34.
Creim, H., Andrae, U., Göggelmann, W., Hesse, S., Schwarz, L.R., Summer, K.H. (1981): How relevant are high doses in mutagenicity and carcinogenicity studies in animals, In: (Kappas, A., Ed.) Progress in Mutation Research, p. 129–147, Elsevier/North Holland Biomedical Press, Amsterdam.
35.
Hammond, P.B. (1977): Exposure of humans to lead. Ann. Rev. Pharmacol. Toxicol.17, 197–214.
36.
Hammond, E.C., Selikoff, I.J., Seidman, H. (1979). Asbestos exposure, cigarette smoking and death rates. Ann. NY Acad. Sci.330, 473–490.
37.
Hatch, T.F. (1971). Thresholds: Do they exist?. Arch. Env. Hlth.22, 687–689.
38.
Heywood, R. (1981). Target organ toxicity. Toxicol. Letters8, 349–358.
39.
Higginson, J. (1980): Multiplicity of factors involved in cancer patterns and trends. In: (Demopoulos, H.B., Mehlman, MA, Eds.) Cancer and the Environment, p. 113–125.Pathotox. Publ.
40.
Park Forest S., II., Holland, V.R., Saunders, B.C., Rose, F.L, Walpole, A.L. (1974): A safer substitute for benzidine in the detection of blood. Tetrahedron30, 3299–3302.
41.
Hong, K., Trudell, J.R., O'Neil, J.R., Cohen, E.N. (1980). Metabolism of nitrous oxide by human and rat intestinal contents. Anesthesiology52, 16–19.
Hueper, W.C., Wiley, F.H., Wolfe, D.H. (1938): Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J. Industr. Hyg.20, 46–62.
Jaeschke, W.C. (1981): Anatomy of unreasonable risk. Ann. NY Acad. Sci.233, 49–57.
46.
Kato, R. (1961). Modification of the toxicity of strychnine and octomethylpyrophosphoramide (OMPA) induced by pretreatment with phenaglycodol and thiopental. Arzneimittelforsch.11, 797–801.
47.
Lappe, M., Hooper, K., Blake, E., Pfund, N., Gardner, E., Rosenberg, J. (1981). Carcinogens and regulation. Science211, 332–338.
48.
Madhukar, B.V., Matsumura, F. (1981). Differences in the nature of induction of mixed-function oxidase systems of the rat liver among phenobarbital, DDT, 3-methylcholanthrene, and TCDD. Toxicol. Appl. Pharmacol.61, 109–118.
49.
Matsuzawa, T., Nakata, M., Goto, I., Tsushima, M. (1981). Dietary deprivation induces fetal loss and abortion in rabbits. Toxicology22, 255–259.
50.
Maugh, Th.H. (1978): Chemical carcinogenesis: How dangerous are low doses?. Science202, 37–41.
51.
McNamara, B.P. (1976): Long-term versus short-term toxicity tests. In: (Mehlman, M.A., Shapiro, R.E., Blumenthal, H., Eds.) New Concepts in Safety Evaluations, p. 61–115.J. Wiley, New York.
52.
Melick, F.W., Escue, H.M., Naryka, J.J., Mezera, Ra, Wheeler, E.P. (1955). The first reported cases of human bladder tumors due to a new carcinogen: Xenylamtne. J. Urol.74: 760–769.
53.
Miller, J.A. (1970). Carcinogenesis by chemicals: An overview. Cancer Res.30, 559–576.
54.
National Academy of Sciences (1974): How safe is safe?National Academy of Sciences, Washington, D.C.
55.
Newberne, P.M., McConnell, R.C. (1980). Dietary nutrients and contaminants in laboratory animals experimentation. J. Evn. Pathol. Toxicol.4, 105–122.
56.
Nicholson, W.J. (Ed.) (1981): Management of Assessed Risk for Carcinogens. Ann. NY Acad. Sci.233.
57.
Oeser, H. (1979): Krebs: Schicksal oder Verschulden?C. Thieme, Stuttgart
58.
Parke, D.V. (1979): Toxicological consequences of enzyme induction and inhibition. In: (Corrod, J.W., Ed.) Drug Toxicity, 133–150, Taylor & Francis, London.
59.
Parke, D.V., Smith, R.L (Eds.) (1977): Drug Metabolism-From Microbe to Man. Taylor & Francis, London.
60.
Pessayre, D., Wandscheer, J.C., Descatoire, V., Dolder, A., Degott, C., Benhamou, J.P. (1980): Cumulative effects of repeated doses of compounds transformed into reactive metabolites. Biochem. Pharmacol.29. 1041–1047.
61.
Port, R., Schmäl, D., Wahrendorf, J. (1976): Some examples of dose-response studies in chemical carcinogens. Oncology33, 66–71.
62.
Rail, D.P. (1979): The role of laboratory animals studies in estimating carcinogenic risks for man. In: (Davis, W., Rosenfeld, C., Eds.) Carcinogenic Risks Strategies for Intervention. IARC Scientific Publ. No. 25, 179-189.
63.
Rentsch, C., Johnston, A. (1976): The effect of prolonged administration of allylisopropylacetylurea to rats on cytochrome P-450 and other liver haemoproteins. Xenobiotica6, 151–157.
64.
Reuber, M.D. (1978): Carcinogenicity of saccharin. Env. Hlth. Persp.25, 173–200.
65.
Reuber, M.D. (1979): Carcinogenicity of chloroform. Env. Hlth. Persp.31, 171–182.
66.
Ruelius, H.W. (1975): Interaction of drug metabolism with other elements of drug safety evaluation. Drug Metab. Rev. 4 (M. Dekker, New York).
67.
Saracci, R. (1977): Asbestos and lung cancer: An analysis of the epidemiological evidence on the asbestos-smoking interaction. Int J. Cancer20, 323–331.
68.
Schmähl, D., Habs, M., Wolter, S., Kuenstler, K. (1979): Experimental investigation on the influence upon chemical carcinogenesis: Influence of different diets on colon carcinogenesis by 1, 2-dimethylhydrazine in Sprague-Dawley rats. J. Cancer Res. Clin. Oncol.93, 57–66.
69.
Schneiderman, M.A. (1981): Regulation of carcinogens in an imprecise world. Ann. NY Acad. Sci.363, 217–232.
70.
Schulte-Hermann, R. (1974): Induction of liver growth by xenobio-compounds and other stimuli. CRC, Crit Rev. Toxicol.3, 97–158.
71.
Selikoff, I.J., Hammond, E.C. (Eds.) (1979): Health Hazards of Asbestos Exposure, Ann. NY Acad. Sci.330.
72.
Smith, R.F. (1979): NCI Bioassays yield a trail of blunders. Science204, 1287–1292.
73.
Sontag, J.M., Page, N.P., Saffiotti, U. (1976): Guidelines for carcinogenic bioassay in small rodents. NCI Carcinogenesis Technical Report Series No. 1, U.S. DHEW, National Institutes of Health, Bethesda.
74.
Staffa J.A., Mehlman, M.A. (Eds.) (1980): Innovation in cancer risk assessment (ED01 study). J. Env. Pathol. Toxicol. (Spec Issue) 3, No. 3.
Stenram, U., Nordlinder, H. (1968). Delayed death in rats treated with cyclophosphamide. Nature219, 1154–1155.
77.
Stevens, M.T. (1977). An alternative method for the evaluation of organ weight experiments. Toxicology7, 275–281.
78.
Strubelt, O., Dost-Kempf, E., Siegers, C.P., Younes, M., Völpel, M., Pruess, U., Dreckmann, J.G. (1981). The influence of fasting on the susceptibility of mice to hepatotoxic injury. Toxicol. Appl. Pharmacol.60, 66–77.
79.
Sweatman, T.W., Renwick, A.G. (1980). The tissue distribution and pharmacokinetics of saccharin in the rat Toxicol. Appl. Pharmacol.55, 18–31.
80.
Thiede, T., Chievitz, E., Christensen, B. Chr. (1964). Chlomaphazin as a bladder carcinogen. Acta Med. Scand.175, 721–725.
81.
Thyssen, J., Althoff, J., Kimmerle, C., Mohr, U. (1981). Inhalation studies with benzo(a)pyrene in Syrian golden hamsters. J. Nat Cancer Inst.66, 575–577.
82.
Uehleke, H. (1962): Relations between structure, velocity of biological N-hydroxylation, and toxicity of aromatic amines. Proc. I. Intern. Pharmacol. Meeting, Stockholm 1961, vol. 6, 31–37, Pergamon Press, Oxford.
83.
Uehleke, H. (1964): Biologische Oxidation und Reduktion am Stickstoff aromatischer Amino-und Nitroderivate und ihre Folgen für den Organismus. In: (Jucker, E., Ed.) Progress of Drug Research vol. 8, 195–260, Birkhäuser, Basel.
84.
Uehleke, H. (1967). Stimulierung einiger mikrosomaler Fremdstoff-Oxidationen durch Phenobarbital, Methylcholanthren und Chlorphenothan, einzeln und in Kombinationen. Arch. Parmak. u. exp. Path.259, 66–90.
85.
Uehleke, H., Greim, H., Schnitger, F. (1969): Influence of methyl and chloro substitution on the microsomal substrate binding of aniline. Int Symp. The Rational Development and Application of Drugs. Nijmegen, July 1969. Abstr. p. 48.
86.
Uehleke, H. (1971a):. N-hydroxylation. Xenobiotica7, 327–338.
87.
Uehleke, H. (1971b): Stoffwechsel von Arzneimitteln als Ursache von Wirkungen, Nebenwirkungen und Toxizitat. In: (Jucker, E., Ed.) Progress in Drug Research, vol. 15, 147–203, Birkhäuser, Basel.
88.
Uehleke, H. (1973a). Animal data in perspective. Int J. Clin. Pharmacol.8, 239–243.
89.
Uehleke, H. (1973b): The role of cytochrome P-450 in the N-oxidation of individual amines. In: (Estabrook, R.W., Cillette, J.R., Leibmann, K.C., Eds.) Microsomesand Drug Oxidations, p. 299–313, The Williams & Wilkins Co., Baltimore.
90.
Uehleke, H. (1974):The formation and kinetics of reactive drug metabolites in mammals. Mutation Res.25, 159–167.
91.
Uehleke, H. (1977): Molecular structures with inherent toxicity. In: (Bundgaard, H., Juul, P., Kofod, H., Eds.) Drug Design and Adverse Reactions. X. A. Benzon Sympos. 1976, pp. 301–312. Munsgaard-Academic Press, Copenhagen-New York.
92.
Uehleke, H. (1979): Drug absorption and toxicity. In: (Prescott, L.F., Nimmo, W.S., Eds.) Drug Absorption. ADIS Press, New York.
93.
Uehleke, H., Brinkschulte-Freitas, M. (1979): Oral toxicity of an essential oil from Myrtle and adaptive liver stimulation. Toxicology72, 335–342.
94.
Uehleke, H. (1980): Kinetics in Toxicology. In: (Cladke, E., Heimann, E., Eds.) 25 Years of Pharmacokinetics. p. 261–270, C. Fischer, Stuttgart
95.
VanDuuren, B.L., Coldschmidt, B.M., Katz, C., Seidman, I., Paul, J.S. (1974): Carcinogenic activity of aikylating agents. J. Nat Cancer Inst.53, 695–700.
96.
VanDuuren, B.L. (1980): Prediction of carcinogenicity based on structure, chemical reactivity and possible metabolic pathways. J. Env. Pathol. Toxicol.3, 11–34.
97.
VanLogten, M.J., Cupta, B.N., McConnell, E.E., Moore, J.A. (1981): The influence of malnutrition on the toxicity of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) in rats. Toxicology21, 77–80.
98.
Wattenberg, L.W. (1980): Inhibitors of chemical carcinogens. J. Env. Pathol. Toxicol.3, 35–52.
99.
Weisburger, J.H., Williams, G.M. (1981). Carcinogen testing: Current problems and new approaches. Science274, 401–407.
100.
Westermann, E.O. (1962): Discussion. In: (Brodie, B.B., Erdos, E.G., Eds.) Metabolic Factors Controlling Duration of Drug Action. Proc. I. Intern. Pharmacol. Meeting, Stockholm 1961, vol. 6, 205–211, Pergamon Press, Oxford.
101.
Whittemore, A.S. (1980). Mathematical models of cancer and their use in risk assessment. J. Env. Pathol. Toxicol.3, 353–362.
102.
Wilson, R., Doell, B.H., Groger, W., Hope, J., Cellatly, J.B.M. (1970): The physiology of liver enlargement In: (Roe, F.J.C., Ed.) Metabolic Aspects of Food Safety, p. 363–418, Blackwell Scientific Publication, London.
103.
Winick, M. (Ed.) (1977): Nutrition and Cancer. J. Wiley and Sons, New York.
104.
Wolf, F.J. (1980). Effect of overloading pathways on toxicity. J. Env. Pathol. Toxicol.3, 113–134.
105.
Wynder, E. (1980). The environment and cancer prevention. J. Env. Pathol. Toxicol.3, 171–192.
106.
Wynder, E.L., McCoy, G.D., Reddy, B.S., Cohen, L, Hill, P., Spingarn, N.E., Weisburger, J.H. (1981): Nutrition and metabolic epidemiology of cancers of the oral cavity, esophagus, colon, breast, prostata, and stomach. In: (Newell, G.R., Ellison, N.M., Eds.) Nutrition and Cancer: Ethiology and Treatment p. 11–48. Raven Press, New York.
107.
Zbinden, C. (Ed.) (1973): Progress in Toxicology, p. 18, Springer, Berlin-Heidelberg.
